Literature DB >> 33437355

Role of azithromycin in antiviral treatment: enhancement of interferon-dependent antiviral pathways and mitigation of inflammation may rely on inhibition of the MAPK cascade?

Tapan Kumar Mohanta1, Pietro Arina2,3, Nanaocha Sharma4, Paola Defilippi5.   

Abstract

Azithromycin is a macrolide-type antibiotic used against a broad range of bacterial infection, such as respiratory tract, skin, ear, eye infections, and sexually transmitted diseases. The ongoing severe acute respiratory syndrome (SARS) mediated by Corona Virus 2 (CoVid19) is a global health concern and various countries witnessed the loss of precious human life. In fall 2020, the absence of specific suitable medication or vaccine is still a major cause of concern to fight the pandemic while different countries have already started using their own medication and available resources to save the life of their citizens. At the present, in many countries around the world, we witnessed the use of the antibiotic azithromycin towards the medication of CoVid19; even its effect on anti CoVid19 is still controversial. This mini review aims to address whether azithromycin can affect molecular pathway involved in inflammatory immunity upon viral infection, to find out the rationale behind the use of azithromycin in the treatment of CoVid19. Overall, the data show that the mechanism of action of azithromycin in viral infection may be dependent on a global amplification of the interferon-dependent pathways mediating antiviral responses, leading to a reduction of viral replication, together with a strong impairment of the inflammatory pathways, relying on MAPK cascade inactivation. AJTR
Copyright © 2020.

Entities:  

Keywords:  CoVid19; SARS; azithromycin; inflammation; interferon; mitogen activated protein kinase

Year:  2020        PMID: 33437355      PMCID: PMC7791480     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  34 in total

Review 1.  Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?

Authors:  G W Amsden
Journal:  J Antimicrob Chemother       Date:  2004-12-08       Impact factor: 5.790

Review 2.  Multiple control of interleukin-8 gene expression.

Authors:  Elke Hoffmann; Oliver Dittrich-Breiholz; Helmut Holtmann; Michael Kracht
Journal:  J Leukoc Biol       Date:  2002-11       Impact factor: 4.962

Review 3.  Signaling by the JNK group of MAP kinases. c-jun N-terminal Kinase.

Authors:  C Dong; R J Davis; R A Flavell
Journal:  J Clin Immunol       Date:  2001-07       Impact factor: 8.317

4.  Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process.

Authors:  Dat Huu Tran; Ryuichi Sugamata; Tomoyasu Hirose; Shoichi Suzuki; Yoshihiko Noguchi; Akihiro Sugawara; Fuyu Ito; Tomoko Yamamoto; Shoji Kawachi; Kiyoko S Akagawa; Satoshi Ōmura; Toshiaki Sunazuka; Naoki Ito; Masakazu Mimaki; Kazuo Suzuki
Journal:  J Antibiot (Tokyo)       Date:  2019-07-12       Impact factor: 2.649

5.  Zika virus cell tropism in the developing human brain and inhibition by azithromycin.

Authors:  Hanna Retallack; Elizabeth Di Lullo; Carolina Arias; Kristeene A Knopp; Matthew T Laurie; Carmen Sandoval-Espinosa; Walter R Mancia Leon; Robert Krencik; Erik M Ullian; Julien Spatazza; Alex A Pollen; Caleigh Mandel-Brehm; Tomasz J Nowakowski; Arnold R Kriegstein; Joseph L DeRisi
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-29       Impact factor: 11.205

6.  Azithromycin reduces tumor necrosis factor-alpha production in lipopolysaccharide-stimulated THP-1 monocytic cells by modification of stress response and p38 MAPK pathway.

Authors:  S Ikegaya; K Inai; H Iwasaki; H Naiki; T Ueda
Journal:  J Chemother       Date:  2009-08       Impact factor: 1.714

7.  Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells.

Authors:  Aline Schögler; Brigitte S Kopf; Michael R Edwards; Sebastian L Johnston; Carmen Casaulta; Elisabeth Kieninger; Andreas Jung; Alexander Moeller; Thomas Geiser; Nicolas Regamey; Marco P Alves
Journal:  Eur Respir J       Date:  2014-10-30       Impact factor: 16.671

8.  Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.

Authors:  Jacques Fantini; Henri Chahinian; Nouara Yahi
Journal:  Int J Antimicrob Agents       Date:  2020-05-13       Impact factor: 5.283

9.  Azithromycin for severe COVID-19.

Authors:  Catherine E Oldenburg; Thuy Doan
Journal:  Lancet       Date:  2020-09-05       Impact factor: 79.321

10.  Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial.

Authors:  Remo H M Furtado; Otavio Berwanger; Henrique A Fonseca; Thiago D Corrêa; Leonardo R Ferraz; Maura G Lapa; Fernando G Zampieri; Viviane C Veiga; Luciano C P Azevedo; Regis G Rosa; Renato D Lopes; Alvaro Avezum; Airton L O Manoel; Felipe M T Piza; Priscilla A Martins; Thiago C Lisboa; Adriano J Pereira; Guilherme B Olivato; Vicente C S Dantas; Eveline P Milan; Otavio C E Gebara; Roberto B Amazonas; Monalisa B Oliveira; Ronaldo V P Soares; Diogo D F Moia; Luciana P A Piano; Kleber Castilho; Roberta G R A P Momesso; Guilherme P P Schettino; Luiz Vicente Rizzo; Ary Serpa Neto; Flávia R Machado; Alexandre B Cavalcanti
Journal:  Lancet       Date:  2020-09-05       Impact factor: 79.321

View more
  2 in total

1.  Discerning the role of polymyxin B nonapeptide in restoring the antibacterial activity of azithromycin against antibiotic-resistant Escherichia coli.

Authors:  Farah Al-Marzooq; Akela Ghazawi; Saeed Tariq; Lana Daoud; Timothy Collyns
Journal:  Front Microbiol       Date:  2022-09-21       Impact factor: 6.064

2.  Perception, Attitude, and Confidence of Physicians About Antimicrobial Resistance and Antimicrobial Prescribing Among COVID-19 Patients: A Cross-Sectional Study From Punjab, Pakistan.

Authors:  Khezar Hayat; Zia Ul Mustafa; Muhammad Nabeel Ikram; Muhammad Ijaz-Ul-Haq; Irum Noor; Muhammad Fawad Rasool; Hafiz Muhammad Ishaq; Anees Ur Rehman; Syed Shahzad Hasan; Yu Fang
Journal:  Front Pharmacol       Date:  2022-01-04       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.